| |
|
|
| |
Pharmaceuticals ETFs
|
|
 |
| |
About Pharmaceuticals ETFs |
|
Pharmaceuticals ETFS Overview and forecast
The pharmaceutical sector is one of the most controversial sectors on Earth. Cost of medicines is an extremely big issue in the US. The health sector, in general, is seen as a messy, expensive, sector, and costs of medicines are seen as contributing greatly to that situation.
Pharmaceuticals ETFS haven't been quite as badly hit as other sectors, however. The pharmaceutical sector is also seen as a high value, and the pricing patterns have been following market troughs, but the sector has recovered pretty quickly from the sudden downward movements.
Asset mixes are quite diverse in the sector, despite the presence of huge index heavyweight companies like Pfizer, Merck, and Johnson and Johnson. Some or all are present on the holdings lists. The Pharmaceuticals ETFS are based on the sector indexes, but their weighting of these big companies is quite variable.
That weighting approach appears to be contributing some strength to the Pharmaceuticals ETFS. As assets, the big pharmaceuticals are high value stocks, as a rule. They tend to support the unit prices well. These ETFs trade in quite large volumes, millions of units, and the search for quality in the current economic climate has worked in their favor.
(Short term: 6 months)
The pharmaceutical sector tends to do quite well, relative to other sectors, and contains a fair share of blue chips. However, as trading stocks, performance can be jumpy, in the short term. For the Pharmaceuticals ETFS, this behavior affects their performance on any short term analysis, so it may be fairer to assess them on a somewhat longer term basis, as investments, if intending to purchase for upside potentials.
As trading material, however, that behavior can be quite positive for short term investors, and returns can be quite good. The pharmaceuticals haven't attracted the investor fury of other sectors, and their reputation as investments is comparatively healthy. Pharmaceuticals ETFS are potentially good, straightforward investments with obvious upside margins based on average prices.
(Medium term: 2 years)
There are possible issues for the pharmaceutical sector in the course of the current US administration, which is looking closely at a range of health issues including costs of medication. A range of measures in relation to supporting patient financial outlay have been under scrutiny and debate. This, obviously, has the potential to have an immediate impact on Pharmaceuticals ETFs, but it should be noted that there are no clear negative indications for the sector, as a result of these concepts.
In terms of values and prices, the Pharmaceuticals ETFs are expected to benefit from the return of the US economy to a normal state, and the return of investment capital into the markets. Pharmaceuticals, as consumer goods, are to some extent beholden to retail market discretionary spending and disposable income considerations. It's also a very diverse sector, in terms of products and supply chain issues. The economic downturn, if not as obviously murderous to the pharmaceutical stocks, has cramped the style of the sector. Stocks haven't been performing to their market potentials, and if an economic recovery gets under way, the Pharmaceuticals ETFs performance could be very good indeed.
(Long term 5 years)
Over the long term, the pharmaceutical stocks, particularly the major league stocks, are among the best performers on the market. These are considered solid investments, in fact they're considered conservative. The expectation for the Pharmaceuticals ETFs is that they would show a strong improvement, long term.
Both as trading propositions and as long term investments, the Pharmaceuticals ETFs as a group would have to rate as strong, security minded, purchases for investors. It needs to be remembered that the sector contains big, main index-sensitive, stocks, however. The law of gravity will apply when market movements generate reaction or program trading, and because of the big names in the Pharmaceuticals ETFs holdings, the ETFs will react to these moves.
Qualifiers to projections
The main issue with Pharmaceuticals ETFs is that this is a very highly complex market. Pharmaceuticals are subject to a range of influences unlike most other stocks. FDA approvals, legals, production issues, patents, medical issues, consumer issues and retail costs are among the regular price sensitive situations in the sector. Investors are advised to stay current, and be familiar with the issues and ramifications for stock prices.
The Pharmaceuticals ETFs can be good, worthwhile, investments by any standard for that description. However, it is strongly advised that the correct procedures for evaluating any Pharmaceuticals ETF are followed, checking out weightings, stocks, and the returns data for the fund. Not all Pharmaceuticals ETFs are equal. Some are good, healthy index representatives, and some aren't.
|
|
|
| |
|
|
|
|
Last Updated on: 2010-01-14 02:03:40 |
| |
|
|
| |
|
Quotes are updated automatically. Quotes are delayed. Etftips.com has not
reviewed, and in no way endorses the validity the data. Etftips.com shall not be
liable for any actions taken in thereon. All information provided "as is" for
informational purposes only, not intended for trading purposes or advice.
Neither Etftips.com nor any of independent providers is liable for any
informational errors, incompleteness, or delays, or for any action taken in
reliance on information contained herein. By accessing the Etftips.com site, you
agree not to redistribute the information found herein. ETF Values can go up as
well as down.
|
| |
| Copyright EtfTips.com ©2009 |
|
|
| |
|
|
